title: A pediatric case of lymphomatoid granulomatosis with onset after completion of chemotherapy for acute myeloid leukemia.
abstract: In this case report, we present a pediatric case of lymphomatoid granulomatosis (LG) with onset just after the completion of chemotherapy for childhood acute myeloid leukemia (AML). After the completion of maintenance therapy, the patient was admitted to our clinic with a complaint of cough. Radiologic examinations revealed nodular lesions in lungs, liver, and kidney. His bone marrow was in remission. The histopathologic examination of the open lung biopsy was consistent with LG. He received only one cycle of cyclophosphamide and high-dose methyl prednisolone treatment and continued to receive interferon (IFN) alpha-2b therapy for 18 months. This treatment regimen resulted in an excellent response. In conclusion, LG may occur after the treatment of pediatric AML as a rare complication and IFN alpha-2b may be an effective treatment choice in these patients.
authors.affiliation: Department of Pediatric Hematology, Dokuz Eylül University, Faculty of Medicine, Izmir, Turkey. hale.oren@dev.edu.tr
authors.forename: Hale
authors.initials: H
authors.lastname: Oren
authors.forename: Gülersu
authors.initials: G
authors.lastname: Irken
authors.forename: Aydanur
authors.initials: A
authors.lastname: Kargi
authors.forename: Sermin
authors.initials: S
authors.lastname: Ozkal
authors.forename: Canan
authors.initials: C
authors.lastname: Uçar
authors.forename: Hüseyin
authors.initials: H
authors.lastname: Gülen
authors.forename: Murat
authors.initials: M
authors.lastname: Duman
authors.forename: Berna
authors.initials: B
authors.lastname: Atabay
authors.forename: Sebnem
authors.initials: S
authors.lastname: Yilmaz
authors.forename: Arzu
authors.initials: A
authors.lastname: Kovanlikaya
mesh_terms: D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002648:Child; D003520:Cyclophosphamide / Q000008:administration & dosage; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D007680:Kidney Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D007951:Leukemia, Myeloid / Q000188:drug therapy*; D008113:Liver Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D008230:Lymphomatoid Granulomatosis / Q000175:diagnosis* / Q000188:drug therapy; D008297:Male; D008775:Methylprednisolone / Q000008:administration & dosage; D011994:Recombinant Proteins; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D003520:Cyclophosphamide; D008775:Methylprednisolone